ONC
BeiGene, Ltd.
356.00$
-0.8%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.8% | +18.5% | +23.6% | +7.8% | +12.6% | -0.9% | +17.7% | +7.4% | +6.1% | +1.0% | +12.7% | – | |
| – | +9.9% | +18.1% | +10.6% | +23.4% | -5.8% | +2.8% | -0.2% | +19.4% | -27.5% | +17.4% | +4.4% | – | |
| – | -22.8% | +18.6% | +26.2% | +5.1% | +16.4% | -1.5% | +20.8% | +5.7% | +11.5% | -0.7% | +13.7% | – | |
| – | +9.0% | -6.8% | -1.3% | +9.2% | +9.2% | -11.1% | +8.9% | -0.2% | +17.5% | -12.1% | +13.1% | – | |
| – | +13.9% | +2.6% | +3.8% | +2.6% | +10.9% | -9.0% | +17.1% | -1.7% | +5.0% | 0.0% | +6.9% | – | |
| – | +11.4% | -2.7% | +1.1% | +5.9% | +10.0% | -10.1% | +12.9% | -1.0% | +11.2% | -6.4% | +10.0% | – | |
| – | – | – | – | – | – | – | +691.6% | +85.6% | +13.4% | +35.1% | +30.1% | – | |
| – | – | – | – | – | – | – | +14.2% | – | – | -43.5% | +20.8% | – | |
| – | -252.9% | – | – | – | – | – | +376.3% | +47.8% | +1.4% | +73.7% | +20.5% | – | |
| – | +20.5% | -54.0% | +87.5% | +59.1% | +188.7% | -70.5% | -73.4% | +326.9% | +270.6% | -61.5% | +136.8% | – | |
| – | -270.6% | – | – | – | – | – | +7,326.8% | +32.4% | -46.7% | +241.9% | +4.2% | – | |
| – | -230.3% | – | – | – | – | – | +122.7% | +36.5% | +35.0% | +33.8% | +17.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.